ChromoCure Launches Pathologist Collaborative Research Program in Support of Project Boveri: Find the Cure Initiative
March 16 2010 - 7:30AM
Marketwired
ChromoCure, Inc. (PINKSHEETS: KKUR) -- ChromoCure announced today
the launch of its Pathologist Collaborative Research Program in
support of its groundbreaking Project Boveri: Find the Cure
Initiative. Agreements are in place whereby selected pathologists
provide cell samples of historical or current patients to the
Company for analysis by its chromosomal scanning technology. Full
results of the scan and analysis will be provided to the
pathologist. Patient information or history is neither required nor
supplied for the purpose of this research. The scan results will be
compared to the diagnosis of the pathologist. The Company will
continuously build its database of results as part of its larger
clinical pre-trial efforts.
The research collaboration pathologists will be announced in
conjunction with new research agreements.
The Company's proprietary Chromosomal Scanner systems have
proven accurate and efficient in the measurement of the unique
genomic characteristic found in 100% of all cancers and never found
in normal cells. The Company's detection technology has been proven
to have an effective accuracy of 100% for all cancers at all
stages. This is superior to other detection approaches presently
employed by pathologists, including biomarker detection, in every
measurable way.
Research has conclusively and irrefutably demonstrated
aneuploidy as a more accurate predictor of cancer than
cytological/histological analysis or genetic marker-based
diagnostics that are the only other methods in existence today.
ChromoCure's systems measure aneuploidy as the sole means of
detecting cancer presence and measuring cancer progression. The
system has a 100% effective accuracy rate. The Company recently
published its collaborative clinical testing with a major cancer
clinic.
The Company's focus on cancer research is further underscored by
recent major clinical publications that both validate ChromoCure's
chromosomal/aneuploidy theory of cancer and establish the company's
detection approach as the forefront of both cancer detection and
research.
The company's technology and related research opens the way for
non-invasive and non-toxic solutions to cancer therapeutics and
disease eradication. ChromoCure's scanner technologies include
proprietary designs, processes, and algorithms centered on
chromosomal imbalance. They provide the foundation for significant
advantages in delivering important results in diagnosis, therapy
and cure.
The Company invites industry and scientific collaboration
through its "Project Boveri: Find the Cure" initiative.
About ChromoCure
ChromoCure develops and provides proprietary cancer detection
systems and related therapeutic technologies. The Company's
proprietary CS200 Chromosomal Scanner has been proven accurate and
efficient in the measurement of the unique genomic characteristic
found in 100% of all cancers and never found in normal cells. The
Company's detection technology has an effective accuracy of 100%
for all cancers at all stages. The Company believes its technology
will become the worldwide gold standard for cancer detection,
progression measurement, and research for both therapy and cure.
The Company also applies its technology and knowledge to cancer
cure and therapeutics research.
Safe-Harbor Statement
This release contains statements or projections regarding future
performance that is forward-looking statements as defined in the
Private Securities Litigation Reform Act of 1995. Actual results
may differ materially from those projected as a result of certain
risks and uncertainties. The company's filings contain various RISK
FACTORS (and are incorporated herein by reference) and should be
read before any investment decision.
ChromoCure, Inc. www.ChromoCure.com info@chromocure.com Tel
1.775.636.6548
Chromocure (CE) (USOTC:KKUR)
Historical Stock Chart
From Aug 2024 to Sep 2024
Chromocure (CE) (USOTC:KKUR)
Historical Stock Chart
From Sep 2023 to Sep 2024
Real-Time news about Chromocure Inc (CE) (OTCMarkets): 0 recent articles
More ChromoCure, Inc. News Articles